Additionally, it was reported in an in vitro study using MG63.2 osteosarcoma cells that the combination therapy of an NK-1R antagonist, L-733,060 compound, and different chemotherapy drugs used in the treatment of osteosarcoma (doxorubicin, cisplatin, ifosfamide, and mitomycin) increased the anticancer activity of chemotherapy (chemosensititzation) [5] (Figure 1). Here, TACR1 is linked to osteosarcoma.